摘要
目的研究安罗替尼对晚期进展性肉瘤的临床疗效。方法选自2018年6月1日～11月30日就诊于我院的晚期进展性肉瘤患者。评估患者后,给予靶向药物安罗替尼12 mg,每日1次,服用2周,停药1周,3周为1个疗程,直至肿瘤进展迅速或无法耐受毒副作用。有手术指征者先行手术,术后开始服药。采用肿瘤体积和内部影像学变化评价疗效,CTCAE4.03评价不良反应。结果本研究共纳入17例。男10例,女7例,平均年龄(41.7±22.4)岁。其中4例骨肉瘤,3例软骨肉瘤,3例多形性未分化肉瘤,2例上皮样肉瘤,2例平滑肌肉瘤,1例腺泡状软组织肉瘤,1例腹腔促纤维组织增生性小圆细胞瘤,1例纤维肉瘤。无CR,PR 2例(11.76%),SD 11例(64.70%),PD 4例(23.54%),ORR为11.76%,DCR为76.46%。常见的不良反应:食欲减退(35.29%),乏力(23.54%),高血压(11.76%)。结论靶向药物安罗替尼对晚期进展性肉瘤有一定的疗效,且毒副作用可耐受,可作为晚期进展性肉瘤治疗的新途径。
Objective To evaluate the efficacy of advanced progressive sarcoma treated by Anlotinib.Methods From June to November 2018,all advanced progressive sarcoma patients in our hospital were included.After evaluation of status,patients received Anlotinib 12 mg once daily,2-week on/1-week off,in a 3-week cycle.Patients would have surgery first if they had surgical indications.Outcomes were assessed by tumor volume and imagelogy diversity.Toxicity was recorded using CTCAE version 4.03.Results Seventeen patients were enrolled.Ten of them were male,and the others were female,with a mean age of(41.7±22.4)years.Pathological findings:4 osteosarcoma,3 chondrosarcoma,3 undifferentiated polymorphous sarcoma,2 epithelioid sarcoma,2 leiomyosarcoma,1 alveolar soft part sarcoma,1 intraabdominal desmoplastic small round cell tumor,1 fibrosarcoma.2 patients had PR(11.76%),11 patients had SD(64.70%),4 patients had PD(23.54%).The ORR was 11.76%,and DCR was 76.46%.The most common adverse events were anorexia(35.29%),fatigue(23.53%),hypertension(11.76%).Conclusions Anlotinib shows antitumor activity in advanced progressive sarcoma entities with a manageable tolerability,which could be a new treatment approach.
作者
龙作尧
鲁亚杰
李明辉
陈国景
王凤伟
刘冬
黄海
张红梅
王臻
LONG Zuo-vao;LU Ya-jie;LI Minghui;CHEN Guo-jing;WANG Feng-wei;LIU Dong;HUANG Hai;ZHANG Hong-mei;WANG Zhen(Department of Orthopaedic Surgery,Xijing Hospital,the Air Force Military Medical University,Xi'An.Shaanxi,710032,China)
出处
《中国骨与关节杂志》
CAS
2019年第1期3-9,共7页
Chinese Journal of Bone and Joint
